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A randomized, controlled trial evaluated the effectiveness of an intervention that used patient navigators and social workers to improve patient adherence to follow-up eye care compared with usual care. Participants with glaucoma and other eye diseases (N =
344) were identified at primary care clinics in community settings
through telemedicine screening of imaging and then randomized
to enhanced intervention (EI) or usual care (UC). Data on participants’ visits with local ophthalmologists were collected for up to
3 years from randomization. Groups were compared for timely attendance at the first visit with the local ophthalmologist and adherence to recommended follow-up visits.

PEER REVIEWED
Summary
What is already known on this topic?
Nonadherence to follow-up eye care is common among people with glaucoma and other eye diseases. Use of patient navigators and social workers
can increase adherence to eye care appointments.
What is added by this report?
The results of a randomized, controlled trial of patients with glaucoma and
other eye diseases showed that a patient navigation and social work intervention doubled the rate of follow-up adherence in community settings.
What are the implications for public health practice?
Involving patient navigators and social workers in ophthalmic care could
improve care and reduce disease progression.

Results
Timely attendance at the first visit was higher for EI than UC
(74.4% vs 39.0%; average relative risk [aRR] = 1.85; 95% CI,
1.51–2.28; P < .001). Rates of adherence to recommended annual
follow-up during year 1 were 18.6% in the EI group and 8.1% in
the usual care group (aRR = 2.08; 95% CI, 1.14–3.76; P = .02).
The aRR across years 2 and 3 was 3.92 (95% CI, 1.24–12.43; P =
.02).

Conclusion

Abstract
Introduction
Appointment nonadherence is common among people with glaucoma, making it difficult for eye care providers to monitor glaucoma progression. Our objective was to determine whether the use
of patient navigators, in conjunction with social worker support,
could increase adherence to recommended follow-up eye appointments.

An intervention using patient navigators and social workers
doubled the rate of adherence to annual recommended follow-up
eye care compared with usual care in community settings, and was
effective at increasing connections with local ophthalmologists.
Interventions to further improve long-term adherence are needed.

Introduction
Glaucoma is a chronic eye disease resulting in visual field defects
and progressive vision loss and is the leading cause of irreversible
blindness worldwide (1). Among other chronic diseases, diabetes
in particular is associated with increased likelihood of developing

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health
and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.

www.cdc.gov/pcd/issues/2021/20_0567.htm • Centers for Disease Control and Prevention
This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

1

PREVENTING CHRONIC DISEASE

VOLUME 18, E52

PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY

MAY 2021

glaucoma (2,3). Because glaucoma is asymptomatic in early
stages, early detection and timely intervention are critical to prevent vision loss (4). Nonadherence to recommended follow-up eye
examinations reduces care and worsens outcomes (5). Fifty-four
percent of people diagnosed with glaucoma fail to attend followup eye-related appointments (6). Barriers to nonadherence include
health care costs, lack of transportation, and emotional distress
(7,8). These barriers most often affect people of color, who have
lower attendance rates at follow-up eye care appointments than
White patients (9–11).
Patient navigators and social workers can help address barriers to
appointment adherence. Patient navigators direct patients to appropriate health care resources, coordinate and schedule appointments, verify insurance status, and arrange transportation (12,13).
Patient navigation programs have been used in other medical
fields to promote adherence to medication and treatment (14–16).
Few studies have looked at using patient navigators to improve appointment adherence among glaucoma patients, particularly
among previously undiagnosed people with risk factors for glaucoma and eye disease (12,17).
Social workers assess, track, and lessen psychosocial barriers to
care to improve quality of life and patient well-being (7,18). Social workers not only help patients navigate the health care system;
they also provide emotional support, which has been shown to increase appointment adherence (18–20). In one study, a medical social worker in a pediatric ophthalmology setting increased appointment adherence by 45% (19,20). In several observational studies,
glaucoma patients reported that a social worker resolved their issues and supported their keeping appointments with their ophthalmologist (7,21).
The combined use of social workers and patient navigators to improve appointment adherence among glaucoma patients has not
been investigated previously in a controlled, prospective adult
study. Our objective was to determine whether the use of patient
navigators and social workers could increase adherence to recommended follow-up eye appointments among a high-risk population with glaucoma or other eye diseases.

Methods
Study design
The Philadelphia Telemedicine Glaucoma Detection and Followup Study was a prospective, randomized clinical trial that aimed to
address the issue of poor adherence to follow-up eye examinations by providing patient navigator and social worker support to
directly guide participants through the eye care process (22). The
5-year study was conducted by Wills Eye Hospital, funded by the

Centers for Disease Control and Prevention, and registered with
ClinicalTrials.gov (NCT02390245). As described previously (22),
the study’s 2 phases 1) conducted a practice-based telemedicine
screening program for glaucoma and other eye diseases among underserved populations with risk factors for eye disease and 2) evaluated whether a community intervention with patient navigation
and social worker support improved access to and use of eye care.
The study was approved by the Wills Eye Hospital Institutional
Review Board and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all
participants before each phase of the study.
In Phase 1, the study aimed to identify people with undiagnosed
glaucoma and other eye diseases and facilitate their referral to local ophthalmologists. A targeted sample at high risk for eye disease was recruited from 12 community partner organizations and
consisted of African American, Hispanic, and Asian adults over
age 40; adults over age 65 of any race/ethnicity; and people over
age 40 with a family history of glaucoma or currently diagnosed
with diabetes. We enrolled only people who had not seen an ophthalmologist in the previous 12 months (N = 906). After informed
consent was obtained, participants underwent a brief vision
screening in their primary care provider’s (PCP’s) office (Visit 1),
which included measuring visual acuity and intraocular pressure
(IOP), and using fundus (retina) photography. Both retina and
glaucoma specialists used telemedicine to read the images at Wills
Eye Hospital. If the IOP was greater than 30 mm Hg, participants
were immediately referred to a local ophthalmologist (fasttracked). Otherwise, participants with findings suggestive of sightthreatening disease, such as glaucoma, diabetic retinopathy, or hypertensive complications, or with unclear screening results were
invited to return to the same location for a comprehensive eye examination by an ophthalmologist (Visit 2). At Visit 2, visual acuity and IOP were assessed again in addition to an ophthalmologic
examination. Visual field tests were also performed, and visionrelated quality of life was assessed by using the National Eye Institute Vision Function Questionnaire (NEI-VFQ). Previous publications (22) report extensively on this first phase, including detailed methods and recruitment summary and concordance of the
telemedicine eye screening findings and comprehensive examination diagnosis (23).
All participants who completed Visit 2 or who were fast-tracked
were invited to participate in Phase 2 of the study. Phase 2 was a
randomized controlled clinical trial designed to evaluate whether
an enhanced intervention (EI) using patient navigation and social
worker support improved patient adherence to follow-up eye care
over usual care (UC) among those with newly diagnosed or suspected glaucoma or other ocular conditions.
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Recruitment and randomization. Participants consenting to participate in Phase 2 were randomized to either the UC group or the
EI group at a fixed 1:1 allocation ratio by using a masked method
of random permuted blocks. Study coordinators retrieved the randomization and allowed participants to select an ophthalmologist
they would like to follow up with over the next several years from
a list of 20 participating offices located within 5 miles of the
screening site.
Usual care. Participants randomized to UC were given their selected ophthalmologist’s contact information and a copy of their eye
examination results. UC participants were instructed to schedule
an initial appointment with the ophthalmologist (Visit 3). Once
connected to that ophthalmologist, services provided by each local ophthalmology practice generally included telephone calls and/
or text message reminders before appointments. No practices
provided patient navigator or social worker assistance as part of
their usual care during the study period.
Enhanced intervention. Participants randomized to EI received a
team-based intervention that included comprehensive assessment
by a licensed social worker and assistance from patient navigators.
The social worker called EI participants up to 3 times within 2
weeks to conduct an initial assessment, explain the EI process, assess participants’ understanding of their new or existing ocular
diagnosis, and document current and past barriers to obtaining eye
care. The social worker provided community resources for participants in need of food and medications at no cost or at a reduced
cost and discussed options for transportation to the local ophthalmologist. The social worker also assessed the participant’s ability
to complete their activities of daily living and provided emotional
support. EI participants interacted by telephone with the social
worker at least 3 times per year over 2 years.
Wills Eye Hospital study managers, ocular technicians, and research assistants served as patient navigators for EI participants.
Their responsibilities included calling participants to schedule appointments; confirming appointments by mail, email, and/or text
messaging; arranging transportation through Customized Community Transportation and Philadelphia Paratransit Service; and
scheduling language interpreters with medical training to participate in eye examinations as needed. Patient navigators were able to
identify cultural and language differences and were aware of
health literacy issues. When possible, navigators were race and
language concordant with the patient population.
Management and follow-up examinations. At Visit 3 and each
follow-up visit, the local ophthalmologist assessed the
participant’s ocular, medical, and family history and conducted a
comprehensive eye examination based on their clinical practice.

The ophthalmologist would reconfirm ocular diagnoses, perform
testing, adjust treatment recommendations as needed, and recommend follow-up intervals for the participant.
Final study visit. All randomized participants were invited to a final visit at their PCP’s office at the end of the follow-up period. At
this visit, the NEI-VFQ was re-administered, visual acuity and
IOP were measured, and overall participant satisfaction with the
study was assessed.
Outcome assessment. The research staff visited local ophthalmologists’ offices to record visit dates, indications, findings, and treatments for up to 3 years from Visit 2. Data collection closed in
March 2019.
Annual adherence. The primary outcome measure was adherence
to recommended follow-up eye care appointments after Visit 3.
Adherence was assessed annually on the basis of the expected
follow-up schedule defined at the index visit for that year. In the
first year, the follow-up recommendation given at Visit 3 by the
ophthalmologist was classified into 1 of 4 categories: return within 2 months, return in 3 to 4 months, return in 6 months, or return
in 12 months. This follow-up recommendation was then translated into the corresponding expected number of visits per year: 6,
3, 2, or 1. Participants were classified as adherent if the number of
visits made within 13 months of Visit 3 (395 days) met or exceeded this expected number. Those who attended fewer visits or
did not attend the initial visit with the local ophthalmologist within 12 months were deemed nonadherent for the first year. Adherence in the second and third years of follow-up was similarly
defined; however, the follow-up recommendation used to define
the required number of visits was based on the patient’s most recent visit with the ophthalmologist before the start of that followup year. That is, the last visit that occurred during the first year of
follow-up determined the follow-up schedule applied to the
second year; similarly, the last visit that occurred during the
second year of follow-up determined the follow-up schedule for
the third year. When no visit occurred during a given year, the previous follow-up recommendation was carried forward. Additional
measures of intervention effectiveness were explored, as detailed
below.
Visit 3 attendance — initial visit with local ophthalmologist. The
study evaluated the intervention’s effectiveness in achieving the
initial connection with the local ophthalmologist through timely
attendance at Visit 3. Timely attendance was defined as having a
first visit within 12 months of randomization.
Visit 4 attendance — first follow-up visit with local
ophthalmologist. Adherence to the first follow-up visit (Visit 4)
was assessed on the basis of the follow-up recommendation of the
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local ophthalmologist at Visit 3. Participants with follow-up recommended within 2 months were deemed adherent to the first
follow-up visit if they returned within 3 months; for recommended follow-up of 3 to 4 months, 6 months, or 12 months, patients
were considered adherent to Visit 4 within 6, 12, or 15 months, respectively.

modeled by Poisson regression with follow-up time from randomization as the offset. An exploratory subset analysis was performed for participants with glaucoma-related diagnoses (those diagnosed with glaucoma, glaucoma suspect, or ocular hypertension). All analyses were performed by using SAS 9.4 and SAS/
STAT 14.3 (SAS Institute).

Total number of visits with local ophthalmologist. The total number of visits included all visits on distinct days occurring after randomization, including Visit 3.

Results

Satisfaction. A brief questionnaire was administered at the final
study visit to assess overall satisfaction. By using a 4-point Likerttype scale, participants were asked to state their satisfaction with
the study and the local ophthalmologist, perceived helpfulness of
the study toward understanding their recommended eye-care, and
likeliness to continue with follow-up care at the local ophthalmologist.

From April 2015 through February 2017, 906 participants completed the telemedicine eye vision screening (Visit 1) with their
PCP as part of Phase 1 of this 5-year study (Figure 1) (22). On
telemedicine reading, 355 participants (39%) were classified as
having normal fundus images. The remaining 551 participants had
abnormal or suspicious fundus images (334, 37%), unreadable
fundus images (155, 17%), or IOP exceeding 21 mm Hg (62, 7%).
Fifteen participants had IOP >30 mm Hg that required fast-track
referral to the local ophthalmologist. The other 536 participants
were invited to have a comprehensive eye examination by their
PCP; 347 participants (65%) attended this Visit 2. These 347 patients and the 15 fast-tracked patients were invited to participate in
Phase 2. A total of 344 participants consented and were randomized to either EU (n = 172) or UC (n = 172). Participants were followed up for a minimum of 22 months post-randomization.

Statistical analysis
The study was designed to detect a 20% difference in adherence
rates between groups during the first year of follow-up by using a
2-tailed test with α = 0.025. With a final sample size of at least
135 participants per group, power to detect such a difference was
86% when the overall adherence across both study arms was 50%.

Participant characteristics

Participant characteristics at Visits 1 and 2 were summarized by
randomization arm by using means and SDs or number and percentages. Adjusted estimates of the relative risk (aRR) of timely
attendance at Visit 3 were calculated by using Poisson regression
in a generalized estimating equation framework (24). An extension of this model for longitudinal data was used to jointly model
repeated annual measures of follow-up adherence (25). The longitudinal model included time (year 1, 2, or 3), randomization assignment, and randomization by time interaction. Both models adjusted for baseline characteristics believed to be associated with adherence to follow-up: Visit 2 recommended follow-up (as a surrogate for disease severity), age at screening, sex, insurance type,
and baseline NEI-VFQ composite score.
In the longitudinal model, 2 relative risks were calculated and 2
hypotheses were tested: 1) comparing randomization groups at
year 1 to assess differences in early adherence and 2) calculating
the average effect of randomization group across years 2 and 3 to
test the long-term efficacy of the intervention. Each test was performed with α = 0.025. Supporting analyses compared groups with
respect to the percentage of participants who attended any visits
with the local ophthalmologist, the percentage of participants who
were adherent to their first post-Visit 3 visit, and the total number
of visits after randomization. Analyses of dichotomous end points
used the same approach as Visit 3 analysis. Number of visits was
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
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first visit was 57 days (interquartile range [IQR]: 39–92) in EI and
47 days (IQR: 27–82) in UC. Rates of any attendance at the local
ophthalmologist were also higher in EI (77.9% vs 41.3%; aRR =
1.83; 95% CI, 1.51–2.22; Table 2) although only 6 EI and 4 UC
participants ever attended a later visit after failing to make contact
with the ophthalmologist in the first 12 months.
Adherence to follow-up after Visit 3. In year 1, the adherence rate
was 18.6% in the EI group and 8.1% in UC with an aRR of 2.08
(95% CI, 1.14–3.76; P = .016) indicating that the intervention significantly increased the rate of adherence (Figure 2) (Table 3). Adherence was relatively stable in years 2 and 3 for EI, while declining over time in UC. The average aRR of adherence across years 2
and 3 was 3.92 (95% CI, 1.24–12.43; P = .02). Results were similar in an exploratory analysis of the glaucoma-related diagnosis
subset with an aRR of 2.30 for year 1 adherence (95% CI,
1.10–4.82) and 3.44 across years 2 and 3 (95% CI, 1.11–10.63)
(Table 3).

Figure 1. Flow chart describing the Philadelphia Telemedicine Glaucoma
Detection and Follow-up Study, indicating participant inclusion, exclusion, and
randomization to the usual care group or enhanced intervention group.

The mean age of participants was 59.9 years at screening; most
(59%) were women and 66% were African American (Table 1).
Roughly two-thirds (n = 230, 66.9%) had a glaucoma-related diagnosis at Visit 2 or were fast-tracked to visit an ophthalmologist
because of high IOP. An NEI-VFQ average composite score of 82
indicated somewhat diminished vision-related quality of life. We
saw no large differences in randomization groups with respect to
baseline characteristics, although the EI group had a slightly higher percentage of women and a lower percentage of participants
with diabetes (Table 1).
Timely Visit 3 attendance. About half of participants (56.7%
[74.4% EI, 39.0% UC]) attended the initial visit with the local
ophthalmologist within 12 months of randomization (Table 2). In
adjusted analysis (Table 2), the EI group showed an 85% relative
increase in timely Visit 3 attendance (adjusted relative risk [aRR]
= 1.85; 95% CI, 1.51–2.28; P < .001). The effect was similar in
the subset of participants with glaucoma-related diagnoses (aRR =
1.73; 95% CI, 1.37–2.19; P < .001). Among those who made
timely contact with the local ophthalmologist, the median time to

Figure 2. Adherence to recommended follow-up schedule over time by
intervention group. Visit 3 was the initial visit with the community
ophthalmologist. Timely adherence to Visit 3 was defined as attendance
within 12 months of randomization. Annual adherence in Years 1–3 was
defined as having attended all recommended follow-up visits within 13
months based on the recommended follow-up at the visit closest to the
beginning of the year.

For adherence to the first follow-up visit recommended by the local ophthalmologist (Visit 4), the rate was 56.4% for EI group and
22.7% for UC (aRR = 2.39; 95% CI, 1.78–3.22) (Table 2). The average number of visits per year of follow-up was 0.9 in EI and 0.4
in UC (aRR = 2.07; 95% CI, 1.54–2.78) (Table 2). The proportion
of participants who attended at least 1 visit in the first year of
follow-up was 41.3% in EI and 18.0% in UC (aRR = 2.18; 95%
CI, 1.52–3.12) (Table 2).
Final study visit and satisfaction survey. One-hundred forty-three
participants attended the final study visit at the PCP office (EI, 77;
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UC, 66). Both groups were satisfied or very satisfied with participation in the study (EI, 98.7%; UC, 93.9%), and most participants
in both groups found the study very helpful in understanding and
taking care of their eyes (EI, 64.9%; UC, 54.5%).

was considered the desired follow-up interval throughout the following year. However, recommendations for follow-up could have
varied during the year, and this may have affected our annual adherence results.

Discussion

Our study had several limitations. First, in spite of the improved
adherence in the EI, annual adherence was still unacceptably low
compared to what is necessary for adequate treatment. Second, our
sample size for year 3 limited our ability to assess the long-term
benefit of the intervention. Lastly, different ophthalmologists’ offices used diverse measures to remind patients to return for
follow-up eye examinations, which were not controlled and could
have affected our results.

In analysis of our primary outcome, we found that an intervention
combining the support of patient navigators and social workers
doubled adherence to recommendations for follow-up with a local
ophthalmologist during the first year. These effects were similar
for participants with or without glaucoma-related diagnoses. Much
of this effect was likely due to an 85% relative increase in timely
attendance at the initial visit with the ophthalmologist (Visit 3) for
those randomized to the intervention arm (EI). After the first year,
adherence rates dropped, but were still higher in the EI group.
Our results are similar to previous studies. The UC group in our
study had only 39% attendance at the initial ophthalmologist visit,
similar to results from the Hoffberger program, which provided
free community-based eye screenings to residents of Baltimore,
Maryland, at high risk for eye disease (6). In another prospective
study, after 1 year, participants with glaucoma-related diagnoses
had 82.5% follow-up adherence rates with the help of only patient
navigators in office-based settings, compared with 73.3% in the
usual care group; however, differences were not significant (12).
Adherence in this study was defined as 1 or more visits within 1
year of diagnosis, and these rates were similar to what we observed for the same outcome in our intervention group (74.4%).
Although the UC rate was much lower in our study, it is consistent with low rates seen in another recent study (26).
Patients with glaucoma may face barriers to receiving follow-up
eye care, which should be recognized and addressed. A questionnaire presented to patients in a glaucoma clinic who were referred
to a medical social worker found that the most frequent barrier to
receiving eye care was emotional distress; additional barriers were
cost of visits, lack of insurance, transportation, impairment of
daily activities, and language (7). Another study reported forgetfulness as a major barrier to adherence to follow-up care (27). Degree of depression was also correlated with level of nonadherence
to eye care recommendations (28). The results of our study suggest that combining support of patient navigators and social workers may be effective in reducing these barriers and thereby improving outcomes.
Our low annual adherence rates may be because adherence for the
year was defined on the basis of the follow-up recommendation at
the beginning of the year. For example, if a participant was given
a recommendation during Visit 3 to follow up in 2 months, this

This study targeted a diverse, urban population at risk for glaucoma but not receiving regular eye care. Study results would likely
be generalizable to similar settings, although access to care, insurance rates, and existing support systems are likely to differ in other geographic areas and may affect the benefit of the intervention.
Future studies could consider combining additional interventions
to further increase rates of adherence to follow-up eye care. Other
interventions that may show promise include providing incentives
such as free eyeglass prescriptions or free eyeglasses (26) and
providing other financial incentives to encourage at-risk participants to return for follow-up eye examinations (12). The costs of
the screening phase have been previously reported (22); the costeffectiveness of our adherence intervention is being evaluated. In
conclusion, our study addresses a critical gap in ophthalmic care
by improving adherence to follow-up recommendations by using
patient navigators and social workers. Addressing this gap is important because adherence to eye care contributes to a better prognosis for patients with chronic eye disease. We believe that use
of social workers and patient navigators could be scaled on a national level to decrease the growing burden associated with glaucoma and other sight-threatening eye diseases.
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Tables
Table 1. Demographic and Clinical Characteristics of Subjects (N = 344) Randomized to Usual Care and Intervention Groups, the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study
Characteristic

All (N = 344)

Usual Care (n = 172)

Intervention (n = 172)

Age, y, mean (SD)

59.9 (11.0)

59.0 (10.6)

60.8 (11.4)

Female

202 (58.7)

94 (54.7)

108 (62.8)

Male

142 (41.3)

78 (45.3)

64 (37.2)

African American

223 (66.2)

111 (66.1)

112 (66.3)

White

52 (15.4)

25 (14.9)

27 (16.0)

Sex, n (%)

Race/ethnicitya, n (%)

Asian

16 (4.8)

7 (4.2)

9 (5.3)

Hispanic

37 (11.0)

20 (11.9)

17 (10.1)

More than one race
Family of history glaucoma, n (%)

9 (2.7)

5 (3.0)

4 (2.4)

87 (25.3)

49 (28.5)

38 (22.1)

Current smoker, n (%)

95 (27.6)

45 (26.2)

50 (29.1)

Hypertension, n (%)

237 (68.9)

122 (70.9)

115 (66.9)

Diabetes, n (%)

198 (57.6)

108 (62.8)

90 (52.3)

Medicaid

130 (37.8)

64 (37.2)

66 (38.4)

Medicare

91 (26.5)

40 (23.3)

51 (29.7)

Private

99 (28.8)

54 (31.4)

45 (26.2)

None

24 (7.0)

14 (8.1)

10 (5.8)

Abnormal

218 (63.4)

112 (65.1)

106 (61.6)

Unreadable

85 (24.7)

38 (22.1)

47 (27.3)

Ocular hypertension

41 (11.9)

22 (12.8)

19 (11.0)

Every 3–4 months

54 (15.7)

26 (15.1)

28 (16.3)

Every 6 months

115 (33.4)

59 (34.3)

56 (32.6)

Every 12 months

175 (50.9)

87 (50.6)

88 (51.2)

Lower (better)

0.2 (0.2)

0.2 (0.2)

0.2 (0.2)

Higher (worse)

0.3 (0.4)

0.3 (0.5)

0.3 (0.3)

Insurance type, n (%)

Screening outcome, n (%)

Visit 2 recommended follow-up, n (%)

logMAR visual, mean (SD)

Abbreviations: C/D ratio, cup-to-disc ratio; dB, decibel; IOP, intraocular pressure; logMAR, logarithm of the minimum angle of resolution; NEI-VFQ, National Eye Institute Visual Function Questionnaire.
a
Race was unknown for 7 subjects.
b
IOP was carried forward from visit 1 for 17 subjects (including 14 fast-tracked subjects).
c
C/D ratio was not available for 22 subjects (including 14 fast-tracked subjects).
d
Mean deviation was not available for 19 subjects (including 14 fast-tracked subjects).
e
One subject did not complete the questionnaire; samples sizes vary across subscales.
(continued on next page)
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(continued)
Table 1. Demographic and Clinical Characteristics of Subjects (N = 344) Randomized to Usual Care and Intervention Groups, the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study
Characteristic

All (N = 344)

Usual Care (n = 172)

Intervention (n = 172)

Lower (better)

14.9 (4.4)

15.3 (4.7)

14.5 (4.0)

Higher (worse)

16.6 (5.2)

16.9 (5.3)

16.2 (5.0)

Lower

0.4 (0.2)

0.4 (0.2)

0.4 (0.2)

Higher

0.5 (0.2)

0.5 (0.2)

0.5 (0.2)

Lower

4.7 (5.2)

4.8 (5.5)

4.7 (4.9)

Higher

7.8 (6.3)

8.0 (6.6)

7.5 (5.9)

None

114 (33.1)

52 (30.2)

62 (36.0)

Glaucoma

38 (11.0)

17 (9.9)

21 (12.2)

Glaucoma suspect

153 (44.5)

80 (46.5)

73 (42.4)

25 (7.3)

14 (8.1)

11 (6.4)

b

IOP , mmHg, mean (SD)

C/D Ratioc, mean (SD)

d

Mean deviation , dB, mean (SD)

Glaucoma-related diagnosis, n (%)

Ocular hypertension
Fast-tracked at screening (IOP >30 mm Hg)
NEI-VFQ composite scoree, mean (SD)

14 (4.1)

9 (5.2)

5 (2.9)

82.2 (15.7)

82.1 (16.0)

82.3 (15.5)

Abbreviations: C/D ratio, cup-to-disc ratio; dB, decibel; IOP, intraocular pressure; logMAR, logarithm of the minimum angle of resolution; NEI-VFQ, National Eye Institute Visual Function Questionnaire.
a
Race was unknown for 7 subjects.
b
IOP was carried forward from visit 1 for 17 subjects (including 14 fast-tracked subjects).
c
C/D ratio was not available for 22 subjects (including 14 fast-tracked subjects).
d
Mean deviation was not available for 19 subjects (including 14 fast-tracked subjects).
e
One subject did not complete the questionnaire; samples sizes vary across subscales.
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Table 2. Summary of Adherence Outcomes, the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study
Outcome

Glaucoma (n = 230) RR
(95% CI)

Usual Care (n = 172) n (%)

Intervention (n = 172) n (%)

All (n = 344) RR (95% CI)

Attended Visit 3 within 12 months

67 (39.0)

128 (74.4)

1.85 (1.51–2.28)

1.73 (1.37–2.19)

Attended any visit at local
ophthalmologist

71 (41.3)

134 (77.9)

1.83 (1.51–2.22)

1.69 (1.36–2.09)

14 (8.1)

32 (18.6)

2.08 (1.14–3.76)

2.30 (1.10–4.82)

39 (22.7)

97 (56.4)

2.39 (1.78–3.22)

2.55 (1.79–3.63)

Adherent in Year 1
Adherent to first follow-up visit (Visit 4)
At least 1 visit in Year 1

31 (18.0)

71 (41.3)

2.18 (1.52–3.12)

2.31 (1.48–3.62)

Total visits attended per year

0.4 (0.7)a

0.9 (0.8)a

2.07 (1.54–2.78)

1.99 (1.44–2.74)

Abbreviation: RR, relative risk.
a
Values are mean (SD).
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Table 3. Intervention Effect on Adherence to Follow-up Schedule, by Year of Follow-up, the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study
Variable

Total

Adherent to Follow-Up, n (%)

Adjusted Relative Risk (95% CI)

P Valuea

Year 1
Usual care

172

14 (8.1)

Reference

NA

Intervention

172

32 (18.6)

2.08 (1.14–3.76)

.02

Year 2
Usual care

140

9 (6.4)

Reference

NA

Intervention

129

27 (20.9)

2.90 (1.39–6.02)

.004

Usual care

25

1 (4.0)

Reference

NA

Intervention

25

5 (20.0)

5.30 (0.56–49.95)

.15

Usual care

NA

NA

Reference

NA

Intervention

NA

NA

3.92 (1.24–12.43)

.02

Year 3

Average, year 1–year 2

Glaucoma Subset
Year 1
Usual care

120

9 (7.5)

Reference

NA

Intervention

110

21 (19.1)

2.30 (1.10–4.82)

.03

Usual care

98

7 (7.1)

Reference

NA

Intervention

79

16 (20.3)

2.47 (1.05–5.80)

.04

Year 2

Year 3
Usual care

19

1 (5.3)

Reference

NA

Intervention

18

4 (22.2)

4.80 (0.56–41.17)

.15

Usual care

NA

NA

Reference

NA

Intervention

NA

NA

3.44 (1.11–10.63)

.03

Average, year 2–year 3

Abbreviation: NA, not applicable.
a
P values were calculated by using GEE (generalized estimating equation) Poisson regression models adjusted for Visit 2 recommended follow-up (as a surrogate
of disease severity), age at screening, sex, insurance type, and baseline National Eye Institute Visual Function Questionnaire composite score.
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